Quick Answer
FATE THERAPEUTICS INC reported R&D Expense of $107.83 million for fiscal year 2025.
FATE THERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $107.83M | -20.1% |
| 2024 | $135.00M | -21.8% |
| 2023 | $172.60M | -46.1% |
| 2022 | $320.45M | +48.7% |
| 2021 | $215.52M | +71.6% |
| 2020 | $125.62M | +43.1% |
| 2019 | $87.77M | +56.7% |
| 2018 | $56.02M | +63.1% |
| 2017 | $34.36M | +29.9% |
| 2016 | $26.45M | +33.2% |
| 2015 | $19.86M | +20.8% |
| 2014 | $16.43M | +36.9% |
| 2013 | $12.01M | +0.1% |
| 2012 | $12.00M | +21.7% |
| 2011 | $9.86M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.84M | -25.4% | -5.8% |
| June 30, 2025 | $27.43M | -20.7% | -5.9% |
| March 31, 2025 | $29.14M | -9.3% | -15.9% |
| September 30, 2024 | $34.65M | +1.1% | +0.1% |
| June 30, 2024 | $34.60M | -15.3% | +7.7% |
| March 31, 2024 | $32.14M | -51.0% | -6.2% |
| September 30, 2023 | $34.27M | -57.1% | -16.1% |
| June 30, 2023 | $40.88M | -49.7% | -37.7% |
- FATE THERAPEUTICS INC showed a decrease of -20.1% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, FATE THERAPEUTICS INC’s r&d expense has grown by 993.8% (from $9.86 million to $107.83 million).
- The most recent figure is from FATE THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: